The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention
Heart & Lung; The Journal of Acute and Critical Care, 06/15/2012
Sun TW et al. - High plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI).Methods
- A total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI.
- Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 (≥1.35 mg/L).
- After a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001).
- The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05).
- Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events.
- The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001).